Pharmacologic and Clinical Effects of Lonapalene (RS 43179), a 5-Lipoxygenase Inhibitor, in Psoriasis
- 1 July 1990
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 95 (1) , 50-54
- https://doi.org/10.1111/1523-1747.ep12873300
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Cutaneous Pharmacology: Perspectives on the Growth of Investigation of Mediators of InflammationJournal of Investigative Dermatology, 1989
- Skin Levels of Arachidonic Acid-Derived Inflammatory Mediators and Histamine in Atopic Dermatitis and PsoriasisJournal of Investigative Dermatology, 1986
- The Responses of Normal and Psoriatic Skin to Single and Multiple Topical Applications of Leukotriene B4Journal of Investigative Dermatology, 1985
- Leukotriene B4‐like material in scale of psoriatic skin lesionsBritish Journal of Pharmacology, 1984
- Levels of arachidonic acid and its metabolites in the skin in human allergic and irritant contact dermatitisBritish Journal of Dermatology, 1984
- The Release of Leukotriene B4-like Material in Biologically Active Amounts from the Lesional Skin of patients with PsoriasisJournal of Investigative Dermatology, 1984
- Production of Intraepidermal Microabscesses by Topical Application of Leukotriene B4Journal of Investigative Dermatology, 1984
- PSORIASIS AND LEUKOTRIENE B4The Lancet, 1982
- Chemokinetic activity of arachidonic acid lipoxygenase products on leuocyctes of different speciesProstaglandins, 1980
- Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytesNature, 1980